Transdermal estradiol priming during clonidine stimulation test in non-growth hormone deficient children with short stature: a pilot study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

The diagnosis of growth hormone (GH) deficiency is strongly influenced by age, body mass index and presence of gonadal steroids.

Priming with oral estradiol (E2) is one possible way to overcome the impact of variable levels of sex steroids.

Who Took Part

According to the abstract, 1, patients were involved.

PubMed indexes the participants as young children, children and teenagers, both men and women.

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

Priming with oral estradiol (E2) is one possible way to overcome the impact of variable levels of sex steroids.

Topics PubMed links to this paper include Administration, Cutaneous, Body Height, Clonidine, Drug Interactions, Estradiol, Growth Disorders and Hormones.

What This Means in Plain Language

The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 1, patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2006 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.